Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Daiichi Sankyo Co. Ltd.
Headquarters: Tokyo, Japan
Website: https://www.daiichisankyo.com/...
Year Founded: 2005
Status: Public
Industry Sector: HealthTechnology
CEO: Hiroyuki Okuzawa
Number Of Employees: 18,726
Enterprise Value: $55,801,525,885
PE Ratio: 28.06
Exchange/Ticker 1: Tokyo:4568
Exchange/Ticker 2: N/A
Latest Market Cap: $45,581,996,717
BioCentury | Mar 24, 2025
Data Byte
Petrelintide up front shatters biotech deal record
At nearly $1.7B, Zealand got $300M more than the prior top cash payment
BioCentury | Mar 17, 2025
Deals
AZ acquires cell therapy play Esobiotech, Taiho acquires ADC partner Araris: Deals Report
Plus: Roche partners with Zealand, AZ with Alteogen and more
BioCentury | Feb 18, 2025
Product Development
Remaking Roche
How the once-dominant cancer company has overhauled its strategy for long-term growth
BioCentury | Feb 11, 2025
Data Byte
FDA’s new and supplemental approvals in January
Vertex’s Nav1.8 inhibitor, Axsome’s acute migraine therapy and Daiichi-AZ’s two ADCs for breast cancer among the month’s approvals
BioCentury | Feb 7, 2025
Editor's Commentary
Has interest in ADCs peaked? — a Perspective
Pfizer’s drop of a late-stage ADC this week may signal the ADC frenzy is cooling
BioCentury | Feb 1, 2025
Management Tracks
Daiichi Sankyo to promote Okuzawa to CEO
Plus: New chair at Outlook and an update from Elevation
BioCentury | Feb 1, 2025
Data Byte
Safety of Alzheimer’s therapy again under scrutiny at EMA’s CHMP
Plus: Pfizer’s Tivdak gets CHMP nod, as Daiichi’s Dato-Dxd receives positive opinion in one indication, gets withdrawn in another
BioCentury | Jan 22, 2025
Deals
Simcere snaps up rights to Fermion’s analgesic, a potential Lilly competitor
BioCentury’s latest Deals Report also includes Regenxbio/Nippon, Merus/Biohaven and Daiichi Sankyo/Glycotope
BioCentury | Jan 8, 2025
Data Byte
Seven PDUFA dates on FDA’s January agenda
Decisions include Ozempic for CKD, a non-opioid painkiller, AZ-Daiichi’s TROP2 ADC, and an allogeneic T cell therapy
BioCentury | Dec 11, 2024
Product Development
ROR1 shines as the next promising ADC target
Also in BioCentury’s Clinical Report: ASH readouts from Cardiff Oncology, Arcellx and GSK; plus data from NewAmsterdam, AbbVie and more
Items per page:
1 - 10 of 1459